Compare iShares Core High Dividend ETF (HDV) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core High Dividend ETF vs Novavax Inc — how do they compare? iShares Core High Dividend ETF trades at $28.71 (market cap $14.68B), while Novavax Inc trades at $12.75 (market cap $1.82B). The key difference: iShares Core High Dividend ETF is far larger — about 8.1× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, iShares Core High Dividend ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core High Dividend ETF for 117 Days and Novavax Inc for 59 Days on average.
| HDV | NVAX | |
|---|---|---|
Market Cap | $14.68B | $1.82B |
Volume | 2,925,562 | 6,198,505 |
52-Week High | $29.93 | $12.75 |
52-Week Low | $23.64 | $6.22 |
Typical Hold Time | 117 Days | 59 Days |
Sector | — | Health |
Enterprise Value | — | $1.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HDV (iShares Core High Dividend ETF) trades at $28.82, up 1.91% with strong bullish technical signals from moving averages and oscillators. The ETF recently underwent a significant sector rebalancing, reducing healthcare exposure while increasing energy, staples, and utilities. Current dividend yield is approximately 3% with recent quarterly payouts between $0.06-$0.10 per share. Technical indicators show RSI at 77.74 suggesting potential overbought conditions near-term.
The outlook remains positive given the ETF's sector rotation toward defensive holdings and income focus, though concentration risk has increased with 62% in three sectors. Key risks include interest rate sensitivity and sector concentration, while opportunities lie in defensive positioning during market volatility. The 3% yield provides income appeal but requires monitoring of sector allocations.
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and a strong buy consensus from analysts (73.9% buy ratings). The company reported a net income of $440.3M in 2025, a significant turnaround from prior losses, though 2026 projections show a return to negative margins. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: near-term catalysts include partnership-driven growth and vaccine approvals, but persistent cash burn and projected 2026 losses pose risks. Investor sentiment is buoyed by recent earnings beats and strategic shifts, yet execution on profitability remains critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core High Dividend ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.
Read more on HDV →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
